Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice?

For: All,

This review explains that newer weight‑management medications—especially pathway‑targeted drugs like setmelanotide and appetite‑regulating drugs like semaglutide—are changing obesity care, which may help some families affected by 16p11.2‑related obesity understand why medical treatments, alongside lifestyle support, may be appropriate to discuss with endocrinology and genetics teams rather than relying on diet and exercise alone.